PDEX Quote, Financials, Valuation and Earnings

InfuSystem Holdings, Inc. has a net margin of 25.26% compared to Pro-Dex, Inc.'s net margin of 6.19%. Pro-Dex, Inc.'s return on equity of 31.77% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

Pro-Dex, Inc. has a consensus price target of $56.00, signalling upside risk potential of 44.63%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 61%. Given that InfuSystem Holdings, Inc. has higher upside potential than Pro-Dex, Inc., analysts believe InfuSystem Holdings, Inc. is more attractive than Pro-Dex, Inc..

Pro-Dex, Inc. has a beta of -0.051, which suggesting that the stock is 105.101% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

Pro-Dex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Pro-Dex, Inc. quarterly revenues are $18.5M, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Pro-Dex, Inc.'s net income of $4.7M is higher than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Pro-Dex, Inc.'s price-to-earnings ratio is 11.55x while InfuSystem Holdings, Inc.'s PE ratio is 33.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex, Inc. is 1.84x versus 1.33x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of 25.26% compared to Pro-Dex, Inc.'s net margin of -862.39%. Pro-Dex, Inc.'s return on equity of 31.77% beat VolitionRX Ltd.'s return on equity of --.

Pro-Dex, Inc. has a consensus price target of $56.00, signalling upside risk potential of 44.63%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 685.43%. Given that VolitionRX Ltd. has higher upside potential than Pro-Dex, Inc., analysts believe VolitionRX Ltd. is more attractive than Pro-Dex, Inc..

Pro-Dex, Inc. has a beta of -0.051, which suggesting that the stock is 105.101% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.

Pro-Dex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Pro-Dex, Inc. quarterly revenues are $18.5M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Pro-Dex, Inc.'s net income of $4.7M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Pro-Dex, Inc.'s price-to-earnings ratio is 11.55x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex, Inc. is 1.84x versus 19.19x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of 25.26% compared to Pro-Dex, Inc.'s net margin of -1037.17%. Pro-Dex, Inc.'s return on equity of 31.77% beat Catheter Precision, Inc.'s return on equity of -192.05%.

Pro-Dex, Inc. has a consensus price target of $56.00, signalling upside risk potential of 44.63%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1762.8%. Given that Catheter Precision, Inc. has higher upside potential than Pro-Dex, Inc., analysts believe Catheter Precision, Inc. is more attractive than Pro-Dex, Inc..

Pro-Dex, Inc. has a beta of -0.051, which suggesting that the stock is 105.101% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.392, suggesting its less volatile than the S&P 500 by 239.195%.

Pro-Dex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.

Pro-Dex, Inc. quarterly revenues are $18.5M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. Pro-Dex, Inc.'s net income of $4.7M is higher than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Pro-Dex, Inc.'s price-to-earnings ratio is 11.55x while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex, Inc. is 1.84x versus 9.59x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 25.26% compared to Pro-Dex, Inc.'s net margin of 3.93%. Pro-Dex, Inc.'s return on equity of 31.77% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Pro-Dex, Inc. has a consensus price target of $56.00, signalling upside risk potential of 44.63%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 111.27%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Pro-Dex, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Pro-Dex, Inc..

Pro-Dex, Inc. has a beta of -0.051, which suggesting that the stock is 105.101% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

Pro-Dex, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Pro-Dex, Inc. quarterly revenues are $18.5M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Pro-Dex, Inc.'s net income of $4.7M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Pro-Dex, Inc.'s price-to-earnings ratio is 11.55x while Xtant Medical Holdings, Inc.'s PE ratio is 69.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex, Inc. is 1.84x versus 0.78x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.